Australian Group on Antimicrobial Resistance (AGAR) Australian Gram-negative Sepsis Outcome Programme (GNSOP) Annual Report 2019

Jan M Bell, Alicia Fajardo Lubian, Sally Partridge, Thomas Gottlieb, Jonathan Iredell, Denise A Daley, Geoffrey W Coombs

# Abstract

The Australian Group on Antimicrobial Resistance (AGAR) performs regular period-prevalence studies to monitor changes in antimicrobial resistance in selected enteric gram-negative pathogens. The 2019 survey was the seventh year to focus on bloodstream infections, and included Enterobacterales, *Pseudomonas aeruginosa* and *Acinetobacte*r species.

Eight thousand eight hundred and fifty-seven isolates, comprising Enterobacterales (7,983; 90.1%), P. aeruginosa (764; 8.6%) and Acinetobacter species (110; 1.2%), were tested using commercial automated methods. The results were analysed using Clinical and Laboratory Standards Institute (CLSI) and European Committee on Antimicrobial Susceptibility Testing (EUCAST) breakpoints (January 2020). Of the key resistances, resistance to the third-generation cephalosporin ceftriaxone was found in 13.3%/13.3% (CLSI/EUCAST criteria) of *Escherichia coli* and 8.4%/8.4% of *Klebsiella pneumoniae*. Resistance rates to ciprofloxacin were 16.0%/16.0% for *E. coli*, 10.2%/10.2% for *K. pneumoniae* complex, 5.9%/5.9% for *Enterobacter cloacae c*omplex, and 4.1%/9.3% for *P. aeruginosa*. Resistance rates to piperacillin-tazobactam were 3.2%/5.7%, 4.7%/8.5%, 14.8%/21.4%, and 6.9%/12.5% for the same four species/complex respectively. Twenty-nine isolates from 29 patients were shown to harbour a carbapenemase gene: 15 *bla*IMP-4, five *bla*OXA-181, four *bla*OXA-23 (one with *bla*OXA-58 also), three *bla*NDM-4/5, one *bla*GES-5, and one *bla*IMP-1.

Keywords: Australian Group on Antimicrobial Resistance (AGAR); antibiotic resistance; bacteraemia; gram-negative; *Escherichia coli*; Enterobacter; Klebsiella

# Introduction

Emerging antimicrobial resistance (AMR) in common pathogenic members of the Enterobacterales is a world-wide phenomenon and presents therapeutic problems for practitioners, both in the community and in hospital practice. The Australian Group on Antimicrobial Resistance (AGAR) commenced surveillance of the key gram-negative pathogens, *Escherichia coli* and *Klebsiella* species, in 1992. Surveys have been conducted biennially until 2008 when annual surveys commenced, alternating between community- and hospital-onset infections.[[1]](#footnote-2) In 2004, another genus of gram-negative pathogens in which resistance can be of clinical importance, *Enterobacter* species, was added. *E. coli* is the most common cause of community-onset urinary tract infection; *Klebsiella* species are less common but are known to harbour important resistances. *Enterobacter* species are less common in the community, but of high importance due to intrinsic resistance to first-line antimicrobials used in the community. Taken together, the three groups of species surveyed are considered to be valuable sentinels for multi-resistance and emerging resistance in enteric gram-negative bacilli. In 2013 AGAR commenced the Enterobacteriaceae Sepsis Outcome Programme (EnSOP) which focused on the collection of resistance and some demographic data on all isolates prospectively from patients with bacteraemia. In 2015, *Pseudomonas aeruginosa* and *Acinetobacter* species were added, and the program has been referred to since that date as the Gram-negative Sepsis Outcome Program (GNSOP).

Resistances of particular interest include resistance to ß-lactams due to ß-lactamases, especially extended-spectrum ß-lactamases (ESBLs), which inactivate the third-generation cephalosporins that are normally considered reserve antimicrobials. Other resistances of interest are to agents important for treatment of these serious infections, such as gentamicin; and resistance to reserve agents such as ciprofloxacin, meropenem and colistin.

The objectives of the 2019 surveillance program were to:

* Monitor resistance in Enterobacterales, *P. aeruginosa* and *Acinetobacter* species isolated from blood cultures taken from patients presenting to the hospital or already in hospital;
* Examine the extent of co-resistance and multidrug resistance in the major species;
* Detect emerging resistance to newer last-line agents such as carbapenems and colistin; and
* Examine the molecular basis of resistance to third-generation cephalosporins, quinolones and carbapenems.

# Methods

## Study design

From 1 January to 31 December 2019, 39 institutions across Australia collected either all or up to 200 isolates from different patient episodes of bacteraemia.

## Species identification

Isolates were identified using the routine method for each institution: Vitek®, Phoenix™ automated microbiology systems, or where available matrix assisted laser desorption/ionisation ­– time of flight (MALDI-ToF) mass spectrometry.

## Susceptibility testing

Testing was performed by two commercial semi-automated methods, Vitek 2 (BioMérieux, France) or Phoenix (Becton Dickinson, USA), which are calibrated to the ISO reference standard method of broth microdilution. Commercially available Vitek AST-N246, or Phoenix NMIC-404 and NMIC-422 cards were utilized by all participants throughout the survey period. The CLSI M100 and EUCAST v10.0 breakpoints from January 2020 have been employed in the analysis.1,2

## Multidrug resistance

The definitions used by Magiorakos et al. were applied in this survey,3 where multidrug resistance was defined as resistance to one or more agent in three or more antimicrobial categories. For each species, antimicrobials were excluded from the count if they are affected by natural resistance mechanisms.

## PCR screening and whole genome sequencing

*E. coli*, *Klebsiella* spp., *Proteus* spp. and *Salmonella* spp. with ceftazidime or ceftriaxone minimum inhibitory concentration (MIC) > 1 mg/L, or cefoxitin MIC > 8 mg/L; any other Enterobacterales with cefepime MIC > 1 mg/L; Enterobacterales with ciprofloxacin MIC > 0.25 mg/L; Enterobacterales with meropenem MIC > 0.25 mg/L; *P. aeruginosa* or *Acinetobacter* spp. with meropenem MIC > 4 mg/L; all isolates with amikacin MIC > 32 mg/L; and all isolates with colistin MIC > 4 mg/L were referred to a central laboratory (Centre for Infectious Diseases and Microbiology, The Westmead Institute for Medical Research) and underwent polymerase chain reaction (PCR) to detect selected resistance genes (Centre for Infectious Diseases & Microbiology Laboratory Services, ICPMR, Westmead Hospital) and/or whole genome sequencing (WGS) (Antimicrobial Resistance Laboratory, Microbial Genomics Reference Laboratory, CIDMLS, ICPMR, Westmead Hospital).

All referred isolates, except *P. aeruginosa*, *Acinetobacter* spp., *Salmonella* spp., and Enterobacterales with meropenem MIC > 0.25 mg/L which underwent WGS, were screened using real-time multiplex PCR using published primers to detect ESBLs (*bla*SHV-ESBL with G→A substitution at position 700 and/or 703, *bla*CTX-M groups 1 and 9, *bla*VEB), plasmid-borne AmpC (*bla*CMY-2-like, *bla*DHA) and carbapenemase (*bla*IMP, *bla*NDM, *bla*VIM) genes.4

Assays for other ESBL targets (*bla*ACT/MIR, *bla*KPC, *bla*OXA-48-like, *bla*GES, *bla*SME, *bla*SPM, *bla*AIM, *bla*GIM, *bla*SIM, *bla*OXA-23/24/58); aminoglycoside ribosomal methytransferases (*armA*, *rmtA*, *rmtB*, *rmtC*, *rmtD*, *rmtE*, *rmtF*, *rmtG*, *rmtH*); and mobile colistin resistance genes (*mcr-1*, *mcr-2*, *mcr-3*, *mcr-4*, *mcr-5*) were detected using in-house, NATA-accredited primers and probes in routine use by the Centre for Infectious Diseases & Microbiology Laboratory Services, ICPMR, at Westmead Hospital.

Genomic DNA for WGS was extracted using the DNeasy® Blood & Tissue Kit (Qiagen) according to the manufacturer’s instructions for gram-negative bacteria. WGS was performed by the Antimicrobial Resistance Laboratory, Microbial Genomics Reference Laboratory, CIDMLS, ICPMR, Westmead Hospital using the Illumina NextSeq 500 platform. Data were analysed using a modification of the Nullarbor bioinformatic pipeline,5 incorporating searching contigs against the NCBI AMRFinder database[[2]](#footnote-3) using ABRicate6 and AMRFinder7, followed by a custom AMR-specific pipeline which includes a read-based search using ARIBA8 against the CARD9 and NCBI databases.

# Results

The species isolated, and the numbers of each by onset setting, are listed in Table 1. Enterobacterales accounted for 90.1%, followed by *P. aeruginosa* (8.6%) and *Acinetobacter* species (1.2%). Of the Enterobacterales, three genera—*Escherichia* (61.6%), *Klebsiella* (19.8%) and *Enterobacter* (5.5%)—contributed 86.9% of all isolates. Major resistances and non-susceptibilities for the top six ranked species are listed in Table 2. Non-susceptibility (which includes both intermediate and resistant isolates) has been included for some agents because these figures provide information about important emerging acquired resistances. Multiple acquired resistances by species are shown in Table 3. Multi-resistance was detected in 26.0% of *E. coli* isolates, 11.8% of *K. pneumoniae* complex, and 7.3% of *E. cloacae* complex. A more detailed breakdown of resistances and non-susceptibilities by state and territory is provided in the online AGAR report.

Table 1. Number and proportion of species isolated, by onset setting, blood cultures, 2019

| Species | Percentage (n) | Onset setting percentage (n) | |
| --- | --- | --- | --- |
| Community onset | Hospital onset |
| *Escherichia coli* | 55.5 (4,914) | 83.3 (4,093) | 16.7 (821) |
| *Klebsiella* *pneumoniae* complex | 13.5 (1,193) | 73.0 (871) | 27.0 (322) |
| *Pseudomonas* *aeruginosa* | 8.6 (764) | 56.2 (429) | 43.8 (335) |
| *Enterobacter* *cloacae* complex | 4.8 (427) | 57.4 (245) | 42.6 (182) |
| *Proteus mirabilis* | 3.0 (267) | 84.3 (225) | 15.7 (42) |
| *Klebsiella oxytoca* | 2.7 (239) | 72.4 (173) | 27.6 (66) |
| *Serratia marcescens* | 2.4 (214) | 48.1 (103) | 51.9 (111) |
| *Klebsiella aerogenes* | 1.5 (129) | 62.0 (80) | 38.0 (49) |
| *Salmonella* species (non-typhoidal) | 1.4 (127) | 96.1 (122) | 3.9 (5) |
| *Morganella morganii* | 1.1 (96) | 68.8 (66) | 31.3 (30) |
| *Salmonella* species (typhoidal) | 0.9 (82) | 100.0 (82) | 0.0 (0) |
| *Citrobacter freundii* complex | 0.9 (77) | 68.8 (53) | 31.2 (24) |
| *Acinetobacter baumannii* complex | 0.7 (62) | 56.5 (35) | 43.5 (27) |
| *Citrobacter koseri* | 0.7 (62) | 72.6 (45) | 27.4 (17) |
| *Raoultella ornithinolytica* | 0.2 (20) | 90.0 (18) | 10.0 (2) |
| *Klebsiella* species | 0.2 (19) | 73.7 (14) | 26.3 (5) |
| *Acinetobacter* species | 0.2 (14) | 64.3 (9) | 35.7 (5) |
| *Acinetobacter ursingii* | 0.1 (13) | 69.2 (9) | 30.8 (4) |
| *Providencia rettgeri* | 0.1 (13) | 76.9 (10) | 23.1 (3) |
| *Acinetobacter lwoffii* | 0.1 (12) | 75.0 (9) | 25.0 (3) |
| *Pantoea agglomerans* | 0.1 (12) | 83.3 (10) | 16.7 (2) |
| *Enterobacter* species | 0.1 (11) | 90.9 (10) | 9.1 (1) |
| Other species (total n = 33) | 1.0 (90) | 72.2 (65) | 27.8 (25) |
| **Total** | **8,857** | **76.5 (6,776)** | **23.5 (2,081)** |

Table 2. Non-susceptibility and resistance rates for the top six ranked species tested, 2019

|  |  | *E. coli* (%) | | *K. pneumoniae* complex(%) | | *P. aeruginosa* (%) | | *E. cloacae* complex (%) | | *P. mirabilis* (%) | | *K. oxytoca* (%) | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Antimicrobial | Categorya | CLSI | EUCAST | CLSI | EUCAST | CLSI | EUCAST | CLSI | EUCAST | CLSI | EUCAST | CLSI | EUCAST |
| Ampicillin | I | 1.9 | – | *b* | *b* | na | na | *b* | *b* | 0.0 | – | *b* | *b* |
| R | 54.4 | 56.3 | *b* | *b* | na | na | *b* | *b* | 14.7 | 14.7 | *b* | *b* |
| Amoxicillin-clavulanic acid (2:1)c | I | 14.8 | c | 5.2 | c | na | na | *b* | *b* | 3.4 | c | 3.3 | c |
| R | 7.8 | c | 6.7 | c | na | na | *b* | *b* | 2.1 | c | 6.0 | c |
| Piperacillin-tazobactam | R | 3.2 | 5.7 | 4.7 | 8.5 | 6.9 | 12.5 | 14.8 | 21.4 | 0.0 | 0.0 | 7.9 | 9.2 |
| Cefazolin | R | 17.0 | 24.0 | 11.4 | 13.0 | na | na | *b* | *b* | 2.1 | 16.8 | 24.7 | 56.3 |
| Cefoxitin | R | 3.4 | / | 5.9 | / | na | na | *b* | *b* | 0.4 | / | 0.4 | / |
| Ceftriaxone | NS | 13.4 | 13.4 | 8.7 | 8.7 | na | na | 24.1 | 24.1 | 1.5 | 1.5 | 7.6 | 7.6 |
| Ceftazidime | NS | 7.1 | 13.0 | 7.2 | 9.7 | 9.0 | 9.0d | 21.5 | 24.1 | 0.4 | 0.8 | 1.3 | 3.0 |
| Cefepime | NS | 5.3 | 10.7 | 3.7 | 7.0 | 5.8 | 5.8d | 4.5 | 10.0 | 1.1 | 1.1 | 0.4 | 1.3 |
| Meropenem | NS | 0.2 | 0.1 | 1.1 | 0.9 | 7.2 | 7.2 | 2.6 | 2.1 | 0.8 | 0.4 | 0.0 | 0.0 |
| Ciprofloxacin | NS | 19.5 | 19.5 | 11.5 | 11.5 | 9.3 | 9.3d | 7.1 | 7.1 | 2.3 | 2.3 | 1.7 | 1.7 |
| Gentamicin | R | 9.0 | 9.5 | 5.1 | 5.4 | 0.9 | na | 4.9 | 6.1 | 1.1 | 11.7 | 0.4 | 0.4 |
| Trimethoprim–sulfamethoxazole | R | 30.9 | 30.9 | 16.3 | 16.1 | na | na | 16.9 | 16.9 | 15.8 | 15.8 | 5.0 | 5.0 |
| Nitrofurantoin | R | 0.9 | 0.9 | 30.5 | / | na | na | 11.9 | / | *b* | *b* | 0.9 | / |

– no intermediate category; / no breakpoints defined; na = not applicable (testing not recommended).

a R = resistant, I = intermediate, NS = non-susceptible (intermediate + resistant), using criteria as published by CLSI [2020] and EUCAST [2020].

b Considered largely intrinsically resistant.

c For EUCAST interpretation, the clavulanic acid concentration is fixed at 2 mg/L, rather than the 2:1 ratio of amoxicillin to clavulanic acid used in CLSI guidelines. As all susceptibility test cards used have a 2:1 ratio of amoxicillin to clavulanic acid no EUCAST category has been applied.

d Percent resistant.

**Table 3. Multiple acquired resistances by species, 2019**

|  | Number of acquired resistances (EUCAST breakpoints)a | | | | | | | | | | | | | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  | Non-multi-resistant | | |  | Multi-resistant | | | | | | | |  |
| Species | Total | 0 | 1 | 2 | Cumulative % | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | Cumulative % |
| *Escherichia coli* | 4,358 | 1,720 | 762 | 744 |  | 312 | 274 | 290 | 159 | 64 | 26 | 6 | 1 |  |
| % | 39.5 | 17.5 | 17.1 | 74.0 | 7.2 | 6.3 | 6.7 | 3.6 | 1.5 | 0.6 | 0.1 | 0.0 | 26.0 |
| *Klebsiella pneumoniae* Complexb | 1,064 | 794 | 91 | 53 |  | 23 | 28 | 31 | 20 | 12 | 8 | 4 | na |  |
| % | 74.6 | 8.6 | 5.0 | 88.2 | 2.2 | 2.6 | 2.9 | 1.9 | 1.1 | 0.8 | 0.4 |  | 11.8 |
| *Enterobacter cloacae* complexc | 358 | 234 | 41 | 57 |  | 5 | 12 | 6 | 3 | na | na | na | na |  |
| % | 65.4 | 11.5 | 15.9 | 92.7 | 1.4 | 3.4 | 1.7 | 0.8 |  |  |  |  | 7.3 |
| *Proteus mirabilis* | 235 | 162 | 40 | 15 |  | 8 | 5 | 2 | 2 | 0 | 1 | 0 | 0 |  |
| % | 68.9 | 17.0 | 6.4 | 92.3 | 3.4 | 2.1 | 0.9 | 0.9 | 0.0 | 0.4 | 0.0 | 0.0 | 7.7 |
| *Klebsiella oxytoca*b | 215 | 90 | 94 | 15 |  | 5 | 7 | 3 | 0 | 0 | 1 | 0 | na |  |
| % | 41.9 | 43.7 | 7.0 | 92.6 | 2.3 | 3.3 | 1.4 | 0.0 | 0.0 | 0.5 | 0.0 |  | 7.4 |
| *Salmonella* species (non-typhoidal)d | 119 | 109 | 7 | 2 |  | 0 | 0 | 0 | 1 | 0 | 0 | 0 | na |  |
| % | 91.6 | 5.9 | 1.7 | 99.2 | 0.0 | 0.0 | 0.0 | 0.8 | 0.0 | 0.0 | 0.0 |  | 0.8 |
| *Serratia marcescens*e | 159 | 49 | 76 | 28 |  | 1 | 4 | 1 | 0 | 0 | na | na | na |  |
| % | 30.8 | 47.8 | 17.6 | 96.2 | 0.6 | 2.5 | 0.6 | 0.0 | 0.0 |  |  |  | 3.8 |
| *Klebsiella aerogenes*c | 115 | 71 | 3 | 39 |  | 1 | 1 | 0 | 0 | na | na | na | na |  |
| % | 61.7 | 2.6 | 33.9 | 98.3 | 0.9 | 0.9 | 0.0 | 0.0 |  |  |  |  | 1.7 |

a Antimicrobial categories (agents) included: aminoglycosides (gentamicin or tobramycin or amikacin), antipseudomonal penicillins + β-lactamase inhibitor (piperacillin–tazobactam), carbapenems (meropenem), non-extended cephalosporins (cefazolin), extended-spectrum cephalosporins (ceftriaxone or ceftazidime or cefepime), cephamycins (cefoxitin), fluoroquinolones (ciprofloxacin), folate pathway inhibitors (trimethoprim–sulfamethoxazole), penicillins (ampicillin), and penicillins + β-lactamase inhibitor (amoxicillin-clavulanic acid, CLSI), na = not applicable.

b Antimicrobial categories excluded: penicillins.

c Antimicrobial categories excluded: penicillins, non-extended cephalosporins, cephamycins, penicillins + β-lactamase inhibitor.

d Antimicrobial categories excluded: aminoglycosides.

e Antimicrobial categories excluded: penicillins, non-extended cephalosporins, penicillins + β-lactamase inhibitor.

## *Escherichia coli*

Moderately high levels of resistance to ampicillin (and therefore amoxicillin) were maintained (54.4%/56.3%, CLSI/EUCAST criteria), with lower rates for amoxicillin-clavulanic acid (14.8%/– intermediate, 7.8%/– resistant). Non-susceptibility to third generation cephalosporins was maintained at similar levels to the 2018 survey (ceftriaxone 13.4%/13.4%, ceftazidime 7.1%/13.0%). Moderate levels of resistance were detected to cefazolin (17.0%/24.0%) and trimethoprim–sulfamethoxazole (30.9%/30.9%). Ciprofloxacin non-susceptibility was found in 19.5%/19.5% of *E. coli* isolates. Resistance to gentamicin (9.0%/9.5%), piperacillin-tazobactam (3.2%/5.7%) and cefepime (3.2%/4.1%) was low. Fifteen isolates (0.3%) had elevated meropenem MICs (≥ 0.5 mg/L). For the strains with ESBL phenotype, ciprofloxacin and gentamicin resistance was found in 64.8%/64.8% and 34.2%/34.9% respectively.

Most of the referred *E. coli* with an ESBL phenotype (580/674, 86.1%) harboured Ambler class A ESBL (489/580, 84.3%), plasmid borne class C (pAmpC) (76, 13.1%) or both ESBL and pAmpC (15, 2.6%) genes. Almost all with an ESBL gene (497/504, 98.6%) had *bla*CTX-M types: *bla*CTX-M group 9 (*n* = 249), *bla*CTX-M group 1 (*n* = 246) or both (*n*= 2). *E. coli* with pAmpC harboured mostly *bla*DHA (51/91, 56%) or *bla*CMY-2-like (37/91, 41%) genes or both (*n*= 3).

## *Klebsiella pneumoniae* complex

*K. pneumoniae* complex showed slightly higher levels of resistance to piperacillin-tazobactam than did *E. coli*, but lower rates of resistance to amoxicillin-clavulanic acid, cefazolin, ceftriaxone, ciprofloxacin, gentamicin, and trimethoprim-sulfamethoxazole. Twenty-one *K. pneumoniae* complex isolates (1.8%) had elevated meropenem MICs (see below). A substantial majority of the referred *K. pneumoniae* complex with an ESBL phenotype (92/118; 78.0%) harboured ESBL (76; 82.6%), pAmpC (15; 16.3%) or both ESBL and pAmpC (1; 1.1%) genes. The vast majority with an ESBL gene (72/77; 93.5%) had *bla*CTX-M types, mostly *bla*CTX-M group 1 (62/72; 86.1%). A substantial majority of the *K. pneumoniae* complex with pAmpC harboured *bla*DHA (13/16; 81%).

## *Enterobacter cloacae* complex

Acquired resistance was common among *E. cloacae* complex isolates, to piperacillin-tazobactam (14.8%/21.4%) ceftriaxone (23.4%/23.4%), ceftazidime (21.3%/21.5%) and trimethoprim–sulfamethoxazole (16.9%/16.9%). Cefepime, ciprofloxacin and gentamicin resistance remain at less than 10%. Seventeen (4.0%) *E. cloacae* complex isolates had elevated meropenem MICs.

## Carbapenemases

Overall, 29 isolates (29 patients) in fourteen institutions from four states/territories were found to harbour a carbapenemase gene. *bla*IMP-4 was detected in 15 isolates: *K. pneumoniae* (five), *E. cloacae* (five), *E. hormaechei* (three), one *K. variicola*, and one *E. coli*. *bla*OXA-181 was detected in five *K. pneumoniae*. *bla*NDM-4 was detected in two *K. pneumoniae* and *bla*NDM-5 in one *E. coli*. *bla*OXA-23 was detected in three *A. baumannii*, one of which also harboured *bla*OXA-58, and one *Proteus mirabilis*. Among *Pseudomonas aeruginosa*, one *bla*GES-5 and one *bla*IMP-1 were detected. Just over one quarter of the carbapenemase-producing organisms were from one institution.

# Discussion

AGAR has been tracking resistance in sentinel enteric gram-negative bacteria since 1992. From 2008, surveillance was segregated into hospital- versus community-onset infections. The last year of hospital-onset only surveillance was 2011.10 In 2013, the first survey of antimicrobial resistance among Enterobacterales isolates from bacteraemic patients throughout Australia was conducted using an approach similar to that conducted by the European EARS-Net program. 2019 was the seventh survey of antimicrobial resistance among Enterobacterales, and the fifth for *P. aeruginosa* and *Acinetobacter* spp. from bacteraemic patients through Australia.

Relative to 2018, the percentage resistance in *E. coli* declined for almost two-thirds (7/11; 60%) of the antimicrobial agents tested, and for *K. pneumoniae* complex by half (5/10). AGAR data show a longitudinal trend of increasing *E. coli* resistance to key anti-gram-negative antimicrobial agents, such as ceftriaxone and ciprofloxacin. The steady rise in resistance to fluoroquinolones is more striking in hospital-onset bacteraemia, with a change from 13.7% to 21.3% between 2013 and 2019.

Carbapenem resistance attributable to acquired carbapenemase genes is still uncommon in patients with bacteraemia in Australia, although five different types (IMP, NDM, OXA-48-like, OXA-23, and GES-5) were detected in isolates from fourteen of the participating institutions. Compared with many other countries in our region, resistance rates in Australian gram-negative bacteria are still relatively low,11 but similar to those observed in 2018 in many Northern European countries.12 Resistance to third generation cephalosporins in *E. coli* from bacteraemic patients in Australia is similar to the European Union and European Economic Area average.12

One quarter of *E. coli* and 12% of *K. pneumoniae* complex were multi-resistant. This is likely to drive more broad-spectrum antibiotic use and increase the resistance selection pressure for important reserve classes, especially the carbapenems.

# Acknowledgments

This study was funded by a grant from the Australian Commission on Safety and Quality in Health care.

AGAR gratefully acknowledges the Centre for Infectious Diseases and Microbiology, The Westmead Institute for Medical Research; the Centre for Infectious Diseases and Microbiology Laboratory Services, ICPMR, Westmead Hospital [Justin Ellem and Mitchell Brown] for PCR screening of selected resistance genes; and the Antimicrobial Resistance Laboratory, Microbial Genomics Reference Laboratory, CIDMLS, ICPMR, Westmead Hospital [Jenny Drapper and Andrew Ginn] for performing whole genome sequencing.

Members of AGAR in 2019 were:

## Australian Capital Territory

Peter Collignon and Susan Bradbury, Canberra Hospital

## New South Wales

Thomas Gottlieb and Steven Siarakis, Concord Hospital

Rodney Givney and Kimberly Ross, John Hunter Hospital

Michael Maley and Helen Ziochos. Liverpool Hospital

James Branley and Linda Douglass, Nepean Hospital

Angela Wong, Royal North Shore Hospital

Sebastiaan van Hal and Alicia Beukers, Royal Prince Alfred Hospital

Jock Harkness and David Lorenz, St Vincent’s Hospital Sydney

Monica Lahra and Peter Huntington, Sydney Children's Hospital

Jon Iredell and Andrew Ginn, Westmead Hospital

Peter Newton and Melissa Hoddle, Wollongong Hospital

## Northern Territory

James McLeod, Alice Springs Hospital

Rob Baird and Jann Hennessy, Royal Darwin Hospital

## Queensland

Enzo Binotto and Bronwyn Thomsett, Pathology Queensland Cairns Base Hospital

Graeme Nimmo and Narelle George, Pathology Queensland Central Laboratory, Royal Brisbane and Women’s Hospital

Clare Nourse Pathology Queensland Children’s Hospital

Petra Derrington and Cheryl Curtis, Pathology Queensland Gold Coast University Hospital

Robert Horvath and Laura Martin, Pathology Queensland Prince Charles Hospital

Naomi Runnegar and Joel Douglas, Pathology Queensland Princess Alexandra Hospital

Jennifer Robson and Georgia Peachey, Sullivan Nicolaides Pathology

## South Australia

Kelly Papanaoum and Xiao Ming Chen, SA Pathology, Flinders Medical Centre

Morgyn Warner and Kija Smith, SA Pathology, Royal Adelaide Hospital and Women’s and Children’s Hospital

## Tasmania

Pankaja Kalukottege and Kathy Wilcox, Launceston General Hospital

Louise Cooley and David Jones, Royal Hobart Hospital

## Victoria

Denis Spelman and Chris Lee, Alfred Hospital

Marcel Leroi and Elizabeth Grabsch, Austin Health

Tony Korman, Despina Kotsanas and Kathryn Cisera, Monash Health, Dandenong Hospital, Monash Medical Centre, Monash Children’s Hospital

Andrew Daley and Gena Gonis, Royal Women’s and Children’s Hospital

Mary Jo Waters and Lisa Brenton, St Vincent’s Hospital

## Western Australia

Shalinie Perera and Ian Meyer, Western Diagnostic Pathology, Joondalup Hospital

David McGechie and Denise Daley, PathWest Laboratory Medicine WA, Fiona Stanley Hospital

Chris Blyth, PathWest Laboratory Medicine WA, Perth Children's Hospital

Ronan Murray and Jacinta Bowman, PathWest Laboratory Medicine WA, Sir Charles Gairdner Hospital

Michael Leung, PathWest Laboratory Medicine WA, Northwest WA

Owen Robinson and Geoffrey Coombs, PathWest Laboratory Medicine WA, Royal Perth Hospital

Sudha Pottumarthy-Boddu and Fay Kappler, Australian Clinical Laboratories, St John of God Hospital Murdoch

# Author details

Ms Jan M Bell1

Dr Alicia Fajardo Lubian2,3

A/Prof Sally Partridge2,3,4

A/Prof Thomas Gottlieb3,5

Prof Jonathan Iredell2,3,4

Ms Denise A Daley6

Prof Geoffrey W Coombs7,8

1. University of Adelaide, Adelaide, South Australia, Australia
2. Westmead Institute for Medical Research, Westmead, New South Wales, Australia
3. The University of Sydney, New South Wales, Australia
4. Westmead Hospital, Westmead, New South Wales, Australia
5. Department of Microbiology and Infectious Diseases, Concord Hospital, Concord, New South Wales, Australia
6. Australian Group on Antimicrobial Resistance, Fiona Stanley Hospital, Murdoch, Western Australia, Australia
7. Antimicrobial Resistance and Infectious Diseases (AMRID) Research Laboratory, Murdoch University, Murdoch, Western Australia, Australia
8. Department of Microbiology, PathWest Laboratory Medicine-WA, Fiona Stanley Hospital, Murdoch, Western Australia, Australia

## Corresponding Author

A/Prof Thomas Gottlieb

Telephone: (02) 9767 7533

Email: thomas.gottlieb@health.nsw.gov.au

# References

1. Clinical and Laboratory Standards Institute (CLSI). *Performance Standards for Antimicrobial Susceptibility Testing*. 30th ed. CLSI supplement M100. Clinical and Laboratory Standards Institute, Wayne, Pennsylvania, USA; 2020.
2. European Committee on Antimicrobial Susceptibility Testing (EUCAST). Clinical breakpoints – breakpoints and guidance. Version 10.0, 25 January 2020. Available at: http://www.eucast.org/clinical\_breakpoints/.
3. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. *Clin Microbiol Infect*. 2012;18(3):268–81.
4. Ellem J, Partridge SR, Iredell JR. Efficient direct extended-spectrum β-lactamase detection by multiplex real-time PCR: accurate assignment of phenotype by use of a limited set of genetic markers. *J Clin Microbiol*. 2011;49(8):3074–7.
5. Seemann T, Goncalves da Silva A, Bulach DM, Schultz MB, Kwong JC, Howden BP. *Nullarbor*. San Francisco; Github. Available from: https://github.com/tseemann/nullarbor.
6. Seemann T. *Abricate*. San Francisco; Github. Available from: https://github.com/tseemann/abricate.
7. National Center for Biotechnology Information (NCBI). AMRFinderPlus. [Website.] Bethesda; United States National Library of Medicine, NCBI: 2020. Available from: https://ncbi.nlm.nih.gov/pathogens/antimicrobial-resistance/AMRFinder/.
8. Hunt M, Mather AE, Sánchez-Busó L, Page AJ, Parkhill J, Keane JA et al. ARIBA: rapid antimicrobial resistance genotyping directly from sequencing reads. *Microb Genom*. 2017;3(10):e000131.
9. Alcock BP, Raphenya AR, Lau TTY, Tsang KK, Bouchard M, Edalatmand A et al. CARD 2020: antibiotic resistome surveillance with the comprehensive antibiotic resistance database. *Nucleic Acids Res*. 2020;48(D1):D517–25.
10. Turnidge J, Gottlieb T, Mitchell D, Pearson J, Bell J, for the Australian Group for Antimicrobial Resistance. Gram-negative Survey 2011 Antimicrobial Susceptibility Report. Adelaide; 2011. Available from: http://www.agargroup.org/files/AGAR20GNB0820Report20FINAL.pdf.
11. Sheng WH, Badal RE, Hsueh PR, SMART Program. Distribution of extended-spectrum β-lactamases, AmpC β-lactamases, and carbapenemases among Enterobacteriaceae isolates causing intra-abdominal infections in the Asia-Pacific region: results of the study for Monitoring Antimicrobial Resistance Trends (SMART). *Antimicrob Agents Chemother*. 2013;57(7):2981–8.
12. European Centre for Disease Prevention and Control (ECDC). *Surveillance of antimicrobial resistance in Europe 2018*. Solna: ECDC; 18 Nov 2019. Available from: https://www.ecdc.europa.eu/en/publications-data/surveillance-antimicrobial-resistance-europe-2018.

**Communicable Diseases Intelligence**

ISSN: 2209-6051 Online

**Communicable Diseases Intelligence (CDI) is a peer-reviewed scientific journal published by the Office of Health Protection, Department of Health. The journal aims to disseminate information on the epidemiology, surveillance, prevention and control of communicable diseases of relevance to Australia.**

**Editor:** Tanja Farmer

**Deputy Editor:** Simon Petrie

**Design and Production:** Kasra Yousefi

**Editorial Advisory Board:** David Durrheim, Mark Ferson, John Kaldor, Martyn Kirk and Linda Selvey

**Website**: <http://www.health.gov.au/cdi>

**Contacts**Communicable Diseases Intelligence is produced by:   
Health Protection Policy Branch, Office of Health Protection, Australian Government Department of Health  
GPO Box 9848, (MDP 6) CANBERRA ACT 2601

**Email:** [cdi.editor@health.gov.au](mailto:cdi.editor@health.gov.au)

**Submit an Article**You are invited to submit your next communicable disease related article to the Communicable Diseases Intelligence (CDI) for consideration. More information regarding CDI can be found at: <http://health.gov.au/cdi>.

Further enquiries should be directed to: [cdi.editor@health.gov.au](mailto:cdi.editor@health.gov.au).

This journal is indexed by Index Medicus and Medline.

Creative Commons Licence - Attribution-NonCommercial-NoDerivatives CC BY-NC-ND

© 2020 Commonwealth of Australia as represented by the Department of Health

This publication is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International Licence from <https://creativecommons.org/licenses/by-nc-nd/4.0/legalcode> (Licence). You must read and understand the Licence before using any material from this publication.

**Restrictions**The Licence does not cover, and there is no permission given for, use of any of the following material found in this publication (if any):

* the Commonwealth Coat of Arms (by way of information, the terms under which the Coat of Arms may be used can be found at [www.itsanhonour.gov.au](http://www.itsanhonour.gov.au/));
* any logos (including the Department of Health’s logo) and trademarks;
* any photographs and images;
* any signatures; and
* any material belonging to third parties.

**Disclaimer**Opinions expressed in Communicable Diseases Intelligence are those of the authors and not necessarily those of the Australian Government Department of Health or the Communicable Diseases Network Australia. Data may be subject to revision.

**Enquiries**Enquiries regarding any other use of this publication should be addressed to the Communication Branch, Department of Health, GPO Box 9848, Canberra ACT 2601, or via e-mail to: [copyright@health.gov.au](mailto:copyright@health.gov.au)

**Communicable Diseases Network Australia**Communicable Diseases Intelligence contributes to the work of the Communicable Diseases Network Australia.  
<http://www.health.gov.au/cdna>

1. http://www.agargroup.org.au/agar-surveys. [↑](#footnote-ref-2)
2. https://www.ncbi.nlm.nih.gov/bioproject/PRJNA313047. [↑](#footnote-ref-3)